Cellectar Biosciences, Inc. (CLRB) surged 24.03 percent to $3.51 after gaining $0.68 on Tuesday, following the announcement of updated and mature clinical trial results for its cancer therapy candidate.
The stock is currently trading at $3.51, compared to a previous close of $2.83 on the Nasdaq. It opened at $4.50 and traded between $3.43 and $4.70 during the session, with volume reaching 45.74 million shares.
Following positive 12-month follow-up data from its Phase 2b CLOVER WaM trial, which showed high response rates and durable efficacy for iopofosine I 131 in heavily pretreated patients, strengthening its case for potential accelerated regulatory approval.
The stock has traded between $2.43 and $20.70 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.